Adaptive Biotechnologies president and COO Julie Rubinstein sells $897k shares

Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold shares totaling $897,456 and acquired shares through option exercises valued at $432,706 across multiple transactions from October 22 to October 26, 2026. The transactions were conducted under a Rule 10b5-1 trading plan, which Ms. Rubinstein adopted on November 18, 2025.The insider transactions come as ADPT shares trade at $26.27, near the upper end of the sale price range. The stock has surged 86% over the past six months, though InvestingPro analysis suggests the company is currently overvalued relative to its Fair Value estimate. Investors tracking insider activity can find ADPT among the most overvalued stocks on the platform.

The sales, totaling $897,456, involved common stock at weighted average prices ranging from $24.38 to $26.30 per share. On October 22, Ms. Rubinstein sold 10,181 shares at a weighted average price of $24.38, with individual sale prices ranging from $23.96 to $24.89. An additional 1,700 shares were sold on the same day at a weighted average price of $25.29, with prices ranging from $24.96 to $25.59. On October 23, she sold 4,500 shares at a weighted average price of $24.50 (ranging from $23.82 to $24.79) and 7,381 shares at a weighted average price of $25.28 (ranging from $24.85 to $25.60). The final sales on October 26 included 8,503 shares at a weighted average price of $25.94 (ranging from $25.25 to $26.25) and 3,378 shares at a weighted average price of $26.30 (ranging from $26.25 to $26.42). For each of these transactions, the reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the stated ranges upon request.The biotechnology company, with a market capitalization of $4.07 billion, has demonstrated strong revenue growth of 50% over the last twelve months. InvestingPro Tips highlight that stock price movements are quite volatile, with 8 additional tips available to subscribers offering deeper insights into the company’s financial health and market position.

Concurrently, Ms. Rubinstein acquired a total of 35,643 shares of common stock by exercising stock options at a price of $12.14 per share. These option exercises, totaling $432,706, occurred on October 22, October 23, and October 26, each involving 11,881 shares. The stock options were fully vested and exercisable, with an expiration date of March 4, 2032.

Following these reported transactions, Ms. Rubinstein directly holds 377,802 shares of Adaptive Biotechnologies common stock. She also holds 165,919 derivative securities in the form of stock options, each with a right to buy common stock at $12.14.With earnings scheduled for November 4, 2026, investors seeking comprehensive analysis can access ADPT’s detailed Pro Research Report, part of InvestingPro’s coverage of over 1,400 US equities, which transforms complex financial data into actionable intelligence.

In other recent news, Adaptive Biotechnologies Corporation reported its second-quarter results, which showed an adjusted loss of $0.25 per share, missing the analyst consensus estimate of a loss of $0.14 per share. However, the company exceeded revenue expectations, posting $71.6 million against the anticipated $65.8 million, marking a 22% increase from the previous year. BTIG raised its price target for the company to $34, citing updated guidelines from the National Comprehensive Cancer Network that specifically named Adeptus Biotechnologies’ clonoSEQ NGS assay for minimal residual disease. Furthermore, Guggenheim increased its price target to $25, highlighting the company’s strong performance in volumes and increased usage among clonoSEQ users. BTIG also noted a 49% year-over-year revenue growth in Adeptus Biotechnologies’ core minimal residual disease business and a 43% increase in volume growth for the clonoSEQ MRD test franchise. Additionally, Goldman Sachs initiated coverage with a buy rating and set a price target of $35, indicating a potential 23% upside. These developments reflect a positive outlook from analysts regarding the company’s market position and growth prospects.